[9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-j][1,7]benzodiazonin-11-yl)-N-methylbenzamide

1. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batch Molecular Formula:</td>
<td>C₃₅H₃₀N₄O₄</td>
</tr>
<tr>
<td>Batch Molecular Weight:</td>
<td>570.64</td>
</tr>
<tr>
<td>Physical Appearance:</td>
<td>White solid</td>
</tr>
<tr>
<td>Solubility:</td>
<td>DMSO to 15 mM</td>
</tr>
<tr>
<td>Storage:</td>
<td>Store at -20°C</td>
</tr>
<tr>
<td>Batch Molecular Structure:</td>
<td>![Molecular Structure Image]</td>
</tr>
</tbody>
</table>

2. ANALYTICAL DATA

<table>
<thead>
<tr>
<th>Method</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>HPLC</td>
<td>Shows 99.7% purity</td>
</tr>
</tbody>
</table>
Product Name: PKC 412
Catalog No.: 2992
Batch No.: 5

CAS Number: 120685-11-2
IUPAC Name: [9S-(9α,10β,11β,13α)]-N-(2,3,10,11,12,13-Hexahydro-10-methoxy-9-methyl-1-oxo-9,13-epoxy-1H,9H-diindolo[1,2,3-gh:3',2',1'-lm]pyrrolo[3,4-][1,7]benzodiaza
zonin-11-yl)-N-methylbenzamide

Description:
Broad spectrum protein kinase inhibitor. Inhibits conventional PKC isoforms (α, β, γ), PDGFRβ, VEGFR2, Syk, PKCγ, Flk-1, Fli1, Cdk1/C, PKA, c-Kit, c-Fgr, c-Src, VEGFR1 and EGFR. Displays potent antitumor activity.

Physical and Chemical Properties:
Batch Molecular Formula: C_{35}H_{30}N_{4}O_{4}
Batch Molecular Weight: 570.64
Physical Appearance: White solid

Minimum Purity: >98%

Storage: Store at -20°C

Solubility & Usage Info:
DMSO to 15 mM

This product is supplied as a lyophilized solid and may be very hard to visualize. Solutions should be made by adding solvent directly to the vial. The vial should then be vortexed vigorously to ensure the product has completely dissolved.

Stability and Solubility Advice:
Some solutions can be difficult to obtain and can be encouraged by rapid stirring, sonication or gentle warming (in a 45-60°C water bath).

Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide. Our standard recommendations are:

SOLIDS: Provided storage is as stated on the product label and the vial is kept tightly sealed, the product can be stored for up to 6 months from date of receipt.

SOLUTIONS: We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month. Wherever possible solutions should be made up and used on the same day.

References:

Tenzer et al (2001) The phosphatidylinositide 3'-kinase/Akt survival pathway is a target for the anticancer and radiosensitizing agent PKC412, an inhibitor of protein kinase C. Cancer Res. 61 8203. PMID: 11719451.